nodes	percent_of_prediction	percent_of_DWPC	metapath
Suramin—PLA2G4A—Epirubicin—urinary bladder cancer	0.494	1	CbGbCtD
Suramin—F2—urine—urinary bladder cancer	0.0103	0.0413	CbGeAlD
Suramin—P2RY2—epithelium—urinary bladder cancer	0.01	0.0403	CbGeAlD
Suramin—P2RY2—renal system—urinary bladder cancer	0.00928	0.0374	CbGeAlD
Suramin—SIRT5—prostate gland—urinary bladder cancer	0.00841	0.0339	CbGeAlD
Suramin—P2RX4—prostate gland—urinary bladder cancer	0.00795	0.032	CbGeAlD
Suramin—P2RY2—female reproductive system—urinary bladder cancer	0.00743	0.0299	CbGeAlD
Suramin—FSHR—female reproductive system—urinary bladder cancer	0.00698	0.0281	CbGeAlD
Suramin—SIRT1—prostate gland—urinary bladder cancer	0.00697	0.0281	CbGeAlD
Suramin—ARSA—prostate gland—urinary bladder cancer	0.00688	0.0277	CbGeAlD
Suramin—P2RX4—seminal vesicle—urinary bladder cancer	0.00673	0.0271	CbGeAlD
Suramin—RYR1—prostate gland—urinary bladder cancer	0.00644	0.0259	CbGeAlD
Suramin—SIRT1—seminal vesicle—urinary bladder cancer	0.00589	0.0237	CbGeAlD
Suramin—ARSA—seminal vesicle—urinary bladder cancer	0.00582	0.0234	CbGeAlD
Suramin—SIRT5—renal system—urinary bladder cancer	0.00573	0.0231	CbGeAlD
Suramin—SIRT5—urethra—urinary bladder cancer	0.00563	0.0227	CbGeAlD
Suramin—PLA2G4A—Raltitrexed—Methotrexate—urinary bladder cancer	0.00549	1	CbGdCrCtD
Suramin—P2RX4—renal system—urinary bladder cancer	0.00542	0.0218	CbGeAlD
Suramin—P2RX4—urethra—urinary bladder cancer	0.00532	0.0214	CbGeAlD
Suramin—SIRT1—epithelium—urinary bladder cancer	0.00512	0.0206	CbGeAlD
Suramin—PLA2G2A—prostate gland—urinary bladder cancer	0.00488	0.0196	CbGeAlD
Suramin—SIRT1—renal system—urinary bladder cancer	0.00475	0.0191	CbGeAlD
Suramin—ARSA—renal system—urinary bladder cancer	0.00469	0.0189	CbGeAlD
Suramin—SIRT1—urethra—urinary bladder cancer	0.00466	0.0188	CbGeAlD
Suramin—SIRT5—female reproductive system—urinary bladder cancer	0.00459	0.0185	CbGeAlD
Suramin—RYR1—smooth muscle tissue—urinary bladder cancer	0.00456	0.0184	CbGeAlD
Suramin—P2RX4—female reproductive system—urinary bladder cancer	0.00434	0.0175	CbGeAlD
Suramin—SIRT5—vagina—urinary bladder cancer	0.00415	0.0167	CbGeAlD
Suramin—PLA2G2A—seminal vesicle—urinary bladder cancer	0.00413	0.0166	CbGeAlD
Suramin—P2RX4—vagina—urinary bladder cancer	0.00393	0.0158	CbGeAlD
Suramin—SIRT1—female reproductive system—urinary bladder cancer	0.0038	0.0153	CbGeAlD
Suramin—ARSA—female reproductive system—urinary bladder cancer	0.00376	0.0151	CbGeAlD
Suramin—F2—prostate gland—urinary bladder cancer	0.00368	0.0148	CbGeAlD
Suramin—PLA2G2A—epithelium—urinary bladder cancer	0.00358	0.0144	CbGeAlD
Suramin—RYR1—female reproductive system—urinary bladder cancer	0.00351	0.0141	CbGeAlD
Suramin—PLA2G2A—smooth muscle tissue—urinary bladder cancer	0.00345	0.0139	CbGeAlD
Suramin—SIRT1—vagina—urinary bladder cancer	0.00344	0.0139	CbGeAlD
Suramin—ARSA—vagina—urinary bladder cancer	0.0034	0.0137	CbGeAlD
Suramin—PLA2G4A—prostate gland—urinary bladder cancer	0.00339	0.0137	CbGeAlD
Suramin—PLA2G2A—renal system—urinary bladder cancer	0.00333	0.0134	CbGeAlD
Suramin—PLA2G2A—urethra—urinary bladder cancer	0.00327	0.0132	CbGeAlD
Suramin—RYR1—vagina—urinary bladder cancer	0.00318	0.0128	CbGeAlD
Suramin—PLA2G4A—seminal vesicle—urinary bladder cancer	0.00287	0.0116	CbGeAlD
Suramin—F2—epithelium—urinary bladder cancer	0.00271	0.0109	CbGeAlD
Suramin—SIRT5—lymph node—urinary bladder cancer	0.00268	0.0108	CbGeAlD
Suramin—PLA2G2A—female reproductive system—urinary bladder cancer	0.00266	0.0107	CbGeAlD
Suramin—P2RX4—lymph node—urinary bladder cancer	0.00254	0.0102	CbGeAlD
Suramin—F2—renal system—urinary bladder cancer	0.00251	0.0101	CbGeAlD
Suramin—PLA2G4A—smooth muscle tissue—urinary bladder cancer	0.0024	0.00967	CbGeAlD
Suramin—PLA2G4A—renal system—urinary bladder cancer	0.00231	0.00931	CbGeAlD
Suramin—PLA2G4A—urethra—urinary bladder cancer	0.00227	0.00915	CbGeAlD
Suramin—SIRT1—lymph node—urinary bladder cancer	0.00222	0.00896	CbGeAlD
Suramin—ARSA—lymph node—urinary bladder cancer	0.0022	0.00885	CbGeAlD
Suramin—F2—female reproductive system—urinary bladder cancer	0.00201	0.0081	CbGeAlD
Suramin—PLA2G4A—female reproductive system—urinary bladder cancer	0.00185	0.00746	CbGeAlD
Suramin—PLA2G4A—vagina—urinary bladder cancer	0.00167	0.00674	CbGeAlD
Suramin—PLA2G2A—lymph node—urinary bladder cancer	0.00156	0.00627	CbGeAlD
Suramin—PLA2G4A—lymph node—urinary bladder cancer	0.00108	0.00436	CbGeAlD
Suramin—PLA2G2A—Metabolism—HPGDS—urinary bladder cancer	0.000127	0.000502	CbGpPWpGaD
Suramin—PLA2G2A—Metabolism—ENO2—urinary bladder cancer	0.000127	0.000502	CbGpPWpGaD
Suramin—PLA2G4A—Phospholipid metabolism—PTEN—urinary bladder cancer	0.000127	0.000501	CbGpPWpGaD
Suramin—PLA2G2A—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	0.000126	0.000499	CbGpPWpGaD
Suramin—F2—Metabolism of proteins—IGFBP3—urinary bladder cancer	0.000126	0.000499	CbGpPWpGaD
Suramin—PLA2G4A—Metabolism—UGT2B7—urinary bladder cancer	0.000125	0.000494	CbGpPWpGaD
Suramin—P2RY2—Signaling by GPCR—RHOA—urinary bladder cancer	0.000125	0.000493	CbGpPWpGaD
Suramin—PLA2G2A—Metabolism—GSTT1—urinary bladder cancer	0.000123	0.000487	CbGpPWpGaD
Suramin—ARSA—Metabolism—TYMS—urinary bladder cancer	0.000123	0.000487	CbGpPWpGaD
Suramin—ARSA—Metabolism—GSTM1—urinary bladder cancer	0.000122	0.000482	CbGpPWpGaD
Suramin—ARSA—Metabolism—NCOR1—urinary bladder cancer	0.000122	0.000482	CbGpPWpGaD
Suramin—PLA2G2A—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	0.000121	0.00048	CbGpPWpGaD
Suramin—P2RY2—GPCR downstream signaling—CXCL8—urinary bladder cancer	0.00012	0.000477	CbGpPWpGaD
Suramin—F2—Platelet activation, signaling and aggregation—RHOA—urinary bladder cancer	0.00012	0.000476	CbGpPWpGaD
Suramin—FSHR—Signaling by GPCR—RHOA—urinary bladder cancer	0.00012	0.000476	CbGpPWpGaD
Suramin—PLA2G4A—Platelet activation, signaling and aggregation—IGF1—urinary bladder cancer	0.00012	0.000476	CbGpPWpGaD
Suramin—F2—Peptide ligand-binding receptors—CXCL8—urinary bladder cancer	0.000119	0.000472	CbGpPWpGaD
Suramin—P2RY2—Signaling Pathways—NCOR1—urinary bladder cancer	0.000118	0.000468	CbGpPWpGaD
Suramin—F2—Cell surface interactions at the vascular wall—HRAS—urinary bladder cancer	0.000118	0.000467	CbGpPWpGaD
Suramin—F2—Hemostasis—IFNA2—urinary bladder cancer	0.000117	0.000464	CbGpPWpGaD
Suramin—ARSA—Metabolism—GPX1—urinary bladder cancer	0.000116	0.000461	CbGpPWpGaD
Suramin—FSHR—GPCR downstream signaling—CXCL8—urinary bladder cancer	0.000116	0.000461	CbGpPWpGaD
Suramin—P2RY2—GPCR downstream signaling—IL2—urinary bladder cancer	0.000115	0.000456	CbGpPWpGaD
Suramin—PLA2G4A—Integrated Pancreatic Cancer Pathway—ERBB2—urinary bladder cancer	0.000114	0.000453	CbGpPWpGaD
Suramin—ARSA—Metabolism—ERCC2—urinary bladder cancer	0.000114	0.000453	CbGpPWpGaD
Suramin—FSHR—Signaling Pathways—NCOR1—urinary bladder cancer	0.000114	0.000452	CbGpPWpGaD
Suramin—PLA2G4A—PDGFR-beta signaling pathway—MYC—urinary bladder cancer	0.000114	0.000451	CbGpPWpGaD
Suramin—PLA2G4A—Metabolism—CYP4B1—urinary bladder cancer	0.000112	0.000445	CbGpPWpGaD
Suramin—PLA2G4A—Integrated Pancreatic Cancer Pathway—PTGS2—urinary bladder cancer	0.000112	0.000443	CbGpPWpGaD
Suramin—FSHR—GPCR downstream signaling—IL2—urinary bladder cancer	0.000111	0.00044	CbGpPWpGaD
Suramin—SIRT1—Gene Expression—ESR1—urinary bladder cancer	0.00011	0.000436	CbGpPWpGaD
Suramin—PLA2G4A—Platelet activation, signaling and aggregation—RHOA—urinary bladder cancer	0.00011	0.000436	CbGpPWpGaD
Suramin—P2RY2—Signaling by GPCR—CXCL8—urinary bladder cancer	0.000109	0.000433	CbGpPWpGaD
Suramin—ARSA—Metabolism—MTHFR—urinary bladder cancer	0.000107	0.000426	CbGpPWpGaD
Suramin—PLA2G4A—Hemostasis—IFNA2—urinary bladder cancer	0.000107	0.000424	CbGpPWpGaD
Suramin—PLA2G4A—Metabolism—SLC19A1—urinary bladder cancer	0.000106	0.00042	CbGpPWpGaD
Suramin—F2—Regulation of Actin Cytoskeleton—EGFR—urinary bladder cancer	0.000106	0.000419	CbGpPWpGaD
Suramin—FSHR—Signaling by GPCR—CXCL8—urinary bladder cancer	0.000106	0.000418	CbGpPWpGaD
Suramin—PLA2G4A—PDGFR-beta signaling pathway—KRAS—urinary bladder cancer	0.000105	0.000417	CbGpPWpGaD
Suramin—P2RY2—Signaling by GPCR—IL2—urinary bladder cancer	0.000104	0.000414	CbGpPWpGaD
Suramin—P2RY2—Signaling Pathways—TERT—urinary bladder cancer	0.000104	0.000412	CbGpPWpGaD
Suramin—PLA2G4A—Metabolism—PRSS3—urinary bladder cancer	0.000103	0.00041	CbGpPWpGaD
Suramin—PLA2G2A—Metabolism—NQO1—urinary bladder cancer	0.000102	0.000405	CbGpPWpGaD
Suramin—PLA2G4A—Integrated Pancreatic Cancer Pathway—CCND1—urinary bladder cancer	0.000101	0.000401	CbGpPWpGaD
Suramin—F2—Platelet activation, signaling and aggregation—IL2—urinary bladder cancer	0.000101	0.0004	CbGpPWpGaD
Suramin—FSHR—Signaling by GPCR—IL2—urinary bladder cancer	0.000101	0.0004	CbGpPWpGaD
Suramin—FSHR—Signaling Pathways—TERT—urinary bladder cancer	0.000101	0.000398	CbGpPWpGaD
Suramin—SIRT1—Gene Expression—PPARG—urinary bladder cancer	0.000101	0.000398	CbGpPWpGaD
Suramin—F2—Regulation of Actin Cytoskeleton—KRAS—urinary bladder cancer	9.99e-05	0.000396	CbGpPWpGaD
Suramin—PLA2G2A—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	9.92e-05	0.000393	CbGpPWpGaD
Suramin—PLA2G4A—Integrated Pancreatic Cancer Pathway—CDKN1A—urinary bladder cancer	9.78e-05	0.000387	CbGpPWpGaD
Suramin—PLA2G4A—Integrated Pancreatic Cancer Pathway—PTEN—urinary bladder cancer	9.76e-05	0.000387	CbGpPWpGaD
Suramin—SIRT1—Gene Expression—CREBBP—urinary bladder cancer	9.66e-05	0.000382	CbGpPWpGaD
Suramin—P2RY2—Signaling Pathways—FGFR3—urinary bladder cancer	9.55e-05	0.000378	CbGpPWpGaD
Suramin—PLA2G4A—Integrated Pancreatic Cancer Pathway—EP300—urinary bladder cancer	9.31e-05	0.000369	CbGpPWpGaD
Suramin—P2RY2—Signaling Pathways—ESR1—urinary bladder cancer	9.28e-05	0.000367	CbGpPWpGaD
Suramin—PLA2G4A—Platelet activation, signaling and aggregation—IL2—urinary bladder cancer	9.23e-05	0.000366	CbGpPWpGaD
Suramin—FSHR—Signaling Pathways—FGFR3—urinary bladder cancer	9.23e-05	0.000365	CbGpPWpGaD
Suramin—PLA2G4A—Integrated Pancreatic Cancer Pathway—SRC—urinary bladder cancer	9.05e-05	0.000359	CbGpPWpGaD
Suramin—F2—Signaling Pathways—HDAC4—urinary bladder cancer	9.02e-05	0.000357	CbGpPWpGaD
Suramin—FSHR—Signaling Pathways—ESR1—urinary bladder cancer	8.96e-05	0.000355	CbGpPWpGaD
Suramin—PLA2G4A—PDGFR-beta signaling pathway—HRAS—urinary bladder cancer	8.94e-05	0.000354	CbGpPWpGaD
Suramin—F2—Platelet activation, signaling and aggregation—SRC—urinary bladder cancer	8.81e-05	0.000349	CbGpPWpGaD
Suramin—ARSA—Metabolism—PPARG—urinary bladder cancer	8.71e-05	0.000345	CbGpPWpGaD
Suramin—PLA2G2A—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	8.65e-05	0.000343	CbGpPWpGaD
Suramin—PLA2G2A—Metabolism—GSTP1—urinary bladder cancer	8.53e-05	0.000338	CbGpPWpGaD
Suramin—ARSA—Metabolism—CREBBP—urinary bladder cancer	8.37e-05	0.000332	CbGpPWpGaD
Suramin—F2—Hemostasis—PLAU—urinary bladder cancer	8.31e-05	0.000329	CbGpPWpGaD
Suramin—PLA2G4A—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	8.29e-05	0.000328	CbGpPWpGaD
Suramin—PLA2G4A—Metabolism—TYMP—urinary bladder cancer	8.26e-05	0.000327	CbGpPWpGaD
Suramin—PLA2G2A—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	8.25e-05	0.000327	CbGpPWpGaD
Suramin—PLA2G4A—Signaling Pathways—HDAC4—urinary bladder cancer	8.25e-05	0.000327	CbGpPWpGaD
Suramin—P2RY2—Signaling Pathways—CREBBP—urinary bladder cancer	8.13e-05	0.000322	CbGpPWpGaD
Suramin—PLA2G4A—Integrated Pancreatic Cancer Pathway—MYC—urinary bladder cancer	8.11e-05	0.000321	CbGpPWpGaD
Suramin—PLA2G4A—Platelet activation, signaling and aggregation—SRC—urinary bladder cancer	8.05e-05	0.000319	CbGpPWpGaD
Suramin—P2RY2—Signaling Pathways—IGF1—urinary bladder cancer	8.03e-05	0.000318	CbGpPWpGaD
Suramin—F2—Class A/1 (Rhodopsin-like receptors)—CXCL8—urinary bladder cancer	7.99e-05	0.000317	CbGpPWpGaD
Suramin—P2RY2—Signaling by GPCR—EGFR—urinary bladder cancer	7.99e-05	0.000316	CbGpPWpGaD
Suramin—PLA2G4A—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	7.94e-05	0.000314	CbGpPWpGaD
Suramin—PLA2G4A—Integrated Pancreatic Cancer Pathway—EGFR—urinary bladder cancer	7.93e-05	0.000314	CbGpPWpGaD
Suramin—PLA2G2A—Metabolism—TYMS—urinary bladder cancer	7.93e-05	0.000314	CbGpPWpGaD
Suramin—F2—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—urinary bladder cancer	7.89e-05	0.000313	CbGpPWpGaD
Suramin—FSHR—Signaling Pathways—CREBBP—urinary bladder cancer	7.85e-05	0.000311	CbGpPWpGaD
Suramin—PLA2G2A—Metabolism—NCOR1—urinary bladder cancer	7.83e-05	0.00031	CbGpPWpGaD
Suramin—PLA2G2A—Metabolism—GSTM1—urinary bladder cancer	7.83e-05	0.00031	CbGpPWpGaD
Suramin—FSHR—Signaling Pathways—IGF1—urinary bladder cancer	7.76e-05	0.000307	CbGpPWpGaD
Suramin—FSHR—Signaling by GPCR—EGFR—urinary bladder cancer	7.72e-05	0.000306	CbGpPWpGaD
Suramin—PLA2G4A—Hemostasis—PLAU—urinary bladder cancer	7.6e-05	0.000301	CbGpPWpGaD
Suramin—F2—Signaling Pathways—GLI1—urinary bladder cancer	7.56e-05	0.000299	CbGpPWpGaD
Suramin—PLA2G4A—Integrated Pancreatic Cancer Pathway—TNF—urinary bladder cancer	7.55e-05	0.000299	CbGpPWpGaD
Suramin—P2RY2—Signaling by GPCR—KRAS—urinary bladder cancer	7.55e-05	0.000299	CbGpPWpGaD
Suramin—PLA2G2A—Metabolism—GPX1—urinary bladder cancer	7.5e-05	0.000297	CbGpPWpGaD
Suramin—PLA2G4A—Integrated Pancreatic Cancer Pathway—KRAS—urinary bladder cancer	7.49e-05	0.000297	CbGpPWpGaD
Suramin—PLA2G4A—Metabolism—NAT2—urinary bladder cancer	7.47e-05	0.000296	CbGpPWpGaD
Suramin—F2—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—urinary bladder cancer	7.45e-05	0.000295	CbGpPWpGaD
Suramin—PLA2G2A—Metabolism—ERCC2—urinary bladder cancer	7.37e-05	0.000292	CbGpPWpGaD
Suramin—P2RY2—Signaling Pathways—RHOA—urinary bladder cancer	7.36e-05	0.000291	CbGpPWpGaD
Suramin—FSHR—Signaling by GPCR—KRAS—urinary bladder cancer	7.29e-05	0.000289	CbGpPWpGaD
Suramin—FSHR—Signaling Pathways—RHOA—urinary bladder cancer	7.1e-05	0.000281	CbGpPWpGaD
Suramin—PLA2G2A—Metabolism—MTHFR—urinary bladder cancer	6.92e-05	0.000274	CbGpPWpGaD
Suramin—PLA2G4A—Signaling Pathways—GLI1—urinary bladder cancer	6.91e-05	0.000274	CbGpPWpGaD
Suramin—ARSA—Metabolism—PTGS2—urinary bladder cancer	6.85e-05	0.000272	CbGpPWpGaD
Suramin—F2—Hemostasis—CREBBP—urinary bladder cancer	6.85e-05	0.000271	CbGpPWpGaD
Suramin—P2RY2—Signaling Pathways—ERBB2—urinary bladder cancer	6.81e-05	0.00027	CbGpPWpGaD
Suramin—F2—Hemostasis—IGF1—urinary bladder cancer	6.77e-05	0.000268	CbGpPWpGaD
Suramin—PLA2G4A—Integrated Pancreatic Cancer Pathway—TP53—urinary bladder cancer	6.66e-05	0.000264	CbGpPWpGaD
Suramin—FSHR—Signaling Pathways—ERBB2—urinary bladder cancer	6.58e-05	0.00026	CbGpPWpGaD
Suramin—P2RY2—Signaling Pathways—CXCL8—urinary bladder cancer	6.46e-05	0.000256	CbGpPWpGaD
Suramin—PLA2G4A—Metabolism—RRM2—urinary bladder cancer	6.45e-05	0.000256	CbGpPWpGaD
Suramin—P2RY2—Signaling by GPCR—HRAS—urinary bladder cancer	6.42e-05	0.000254	CbGpPWpGaD
Suramin—F2—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—urinary bladder cancer	6.34e-05	0.000251	CbGpPWpGaD
Suramin—PLA2G4A—Hemostasis—CREBBP—urinary bladder cancer	6.27e-05	0.000248	CbGpPWpGaD
Suramin—FSHR—Signaling Pathways—CXCL8—urinary bladder cancer	6.24e-05	0.000247	CbGpPWpGaD
Suramin—F2—Hemostasis—RHOA—urinary bladder cancer	6.2e-05	0.000246	CbGpPWpGaD
Suramin—FSHR—Signaling by GPCR—HRAS—urinary bladder cancer	6.2e-05	0.000245	CbGpPWpGaD
Suramin—PLA2G4A—Hemostasis—IGF1—urinary bladder cancer	6.19e-05	0.000245	CbGpPWpGaD
Suramin—P2RY2—Signaling Pathways—IL2—urinary bladder cancer	6.17e-05	0.000244	CbGpPWpGaD
Suramin—F2—GPCR ligand binding—CXCL8—urinary bladder cancer	6.09e-05	0.000241	CbGpPWpGaD
Suramin—P2RY2—Signaling Pathways—CCND1—urinary bladder cancer	6.02e-05	0.000238	CbGpPWpGaD
Suramin—ARSA—Metabolism—PTEN—urinary bladder cancer	5.98e-05	0.000237	CbGpPWpGaD
Suramin—PLA2G4A—Metabolism—HPGDS—urinary bladder cancer	5.98e-05	0.000237	CbGpPWpGaD
Suramin—PLA2G4A—Metabolism—ENO2—urinary bladder cancer	5.98e-05	0.000237	CbGpPWpGaD
Suramin—FSHR—Signaling Pathways—IL2—urinary bladder cancer	5.96e-05	0.000236	CbGpPWpGaD
Suramin—PLA2G4A—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	5.94e-05	0.000235	CbGpPWpGaD
Suramin—P2RY2—Signaling Pathways—MMP9—urinary bladder cancer	5.84e-05	0.000231	CbGpPWpGaD
Suramin—P2RY2—Signaling Pathways—CDKN1A—urinary bladder cancer	5.82e-05	0.000231	CbGpPWpGaD
Suramin—FSHR—Signaling Pathways—CCND1—urinary bladder cancer	5.81e-05	0.00023	CbGpPWpGaD
Suramin—P2RY2—Signaling Pathways—PTEN—urinary bladder cancer	5.81e-05	0.00023	CbGpPWpGaD
Suramin—PLA2G4A—Metabolism—GSTT1—urinary bladder cancer	5.8e-05	0.00023	CbGpPWpGaD
Suramin—SIRT1—Gene Expression—MYC—urinary bladder cancer	5.73e-05	0.000227	CbGpPWpGaD
Suramin—PLA2G4A—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	5.71e-05	0.000226	CbGpPWpGaD
Suramin—ARSA—Metabolism—EP300—urinary bladder cancer	5.7e-05	0.000226	CbGpPWpGaD
Suramin—PLA2G4A—Hemostasis—RHOA—urinary bladder cancer	5.67e-05	0.000225	CbGpPWpGaD
Suramin—FSHR—Signaling Pathways—MMP9—urinary bladder cancer	5.64e-05	0.000223	CbGpPWpGaD
Suramin—FSHR—Signaling Pathways—CDKN1A—urinary bladder cancer	5.62e-05	0.000223	CbGpPWpGaD
Suramin—PLA2G2A—Metabolism—PPARG—urinary bladder cancer	5.61e-05	0.000222	CbGpPWpGaD
Suramin—FSHR—Signaling Pathways—PTEN—urinary bladder cancer	5.61e-05	0.000222	CbGpPWpGaD
Suramin—P2RY2—Signaling Pathways—EP300—urinary bladder cancer	5.54e-05	0.000219	CbGpPWpGaD
Suramin—PLA2G2A—Metabolism—CREBBP—urinary bladder cancer	5.39e-05	0.000214	CbGpPWpGaD
Suramin—P2RY2—Signaling Pathways—SRC—urinary bladder cancer	5.38e-05	0.000213	CbGpPWpGaD
Suramin—FSHR—Signaling Pathways—EP300—urinary bladder cancer	5.35e-05	0.000212	CbGpPWpGaD
Suramin—F2—Metabolism of proteins—IGF1—urinary bladder cancer	5.32e-05	0.000211	CbGpPWpGaD
Suramin—F2—Hemostasis—IL2—urinary bladder cancer	5.2e-05	0.000206	CbGpPWpGaD
Suramin—FSHR—Signaling Pathways—SRC—urinary bladder cancer	5.2e-05	0.000206	CbGpPWpGaD
Suramin—F2—Signaling Pathways—RBX1—urinary bladder cancer	5.18e-05	0.000205	CbGpPWpGaD
Suramin—F2—Signaling Pathways—TSC1—urinary bladder cancer	4.87e-05	0.000193	CbGpPWpGaD
Suramin—P2RY2—Signaling Pathways—MYC—urinary bladder cancer	4.83e-05	0.000191	CbGpPWpGaD
Suramin—PLA2G4A—Metabolism—NQO1—urinary bladder cancer	4.82e-05	0.000191	CbGpPWpGaD
Suramin—PLA2G4A—Hemostasis—IL2—urinary bladder cancer	4.76e-05	0.000188	CbGpPWpGaD
Suramin—PLA2G4A—Signaling Pathways—RBX1—urinary bladder cancer	4.74e-05	0.000188	CbGpPWpGaD
Suramin—P2RY2—Signaling Pathways—EGFR—urinary bladder cancer	4.72e-05	0.000187	CbGpPWpGaD
Suramin—PLA2G4A—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	4.67e-05	0.000185	CbGpPWpGaD
Suramin—F2—Hemostasis—EP300—urinary bladder cancer	4.67e-05	0.000185	CbGpPWpGaD
Suramin—FSHR—Signaling Pathways—MYC—urinary bladder cancer	4.66e-05	0.000185	CbGpPWpGaD
Suramin—F2—Signaling Pathways—JAG1—urinary bladder cancer	4.64e-05	0.000184	CbGpPWpGaD
Suramin—FSHR—Signaling Pathways—EGFR—urinary bladder cancer	4.56e-05	0.000181	CbGpPWpGaD
Suramin—F2—Hemostasis—SRC—urinary bladder cancer	4.54e-05	0.00018	CbGpPWpGaD
Suramin—P2RY2—Signaling Pathways—KRAS—urinary bladder cancer	4.46e-05	0.000177	CbGpPWpGaD
Suramin—PLA2G4A—Signaling Pathways—TSC1—urinary bladder cancer	4.45e-05	0.000176	CbGpPWpGaD
Suramin—PLA2G2A—Metabolism—PTGS2—urinary bladder cancer	4.42e-05	0.000175	CbGpPWpGaD
Suramin—FSHR—Signaling Pathways—KRAS—urinary bladder cancer	4.31e-05	0.000171	CbGpPWpGaD
Suramin—F2—Metabolism of proteins—CXCL8—urinary bladder cancer	4.28e-05	0.00017	CbGpPWpGaD
Suramin—PLA2G4A—Hemostasis—EP300—urinary bladder cancer	4.27e-05	0.000169	CbGpPWpGaD
Suramin—PLA2G4A—Signaling Pathways—JAG1—urinary bladder cancer	4.24e-05	0.000168	CbGpPWpGaD
Suramin—PLA2G4A—Hemostasis—SRC—urinary bladder cancer	4.15e-05	0.000164	CbGpPWpGaD
Suramin—PLA2G4A—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	4.08e-05	0.000161	CbGpPWpGaD
Suramin—PLA2G4A—Metabolism—GSTP1—urinary bladder cancer	4.02e-05	0.000159	CbGpPWpGaD
Suramin—P2RY2—Signaling Pathways—TP53—urinary bladder cancer	3.96e-05	0.000157	CbGpPWpGaD
Suramin—F2—GPCR downstream signaling—RHOA—urinary bladder cancer	3.92e-05	0.000155	CbGpPWpGaD
Suramin—PLA2G4A—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	3.89e-05	0.000154	CbGpPWpGaD
Suramin—PLA2G2A—Metabolism—PTEN—urinary bladder cancer	3.85e-05	0.000153	CbGpPWpGaD
Suramin—FSHR—Signaling Pathways—TP53—urinary bladder cancer	3.83e-05	0.000152	CbGpPWpGaD
Suramin—P2RY2—Signaling Pathways—HRAS—urinary bladder cancer	3.79e-05	0.00015	CbGpPWpGaD
Suramin—F2—Hemostasis—KRAS—urinary bladder cancer	3.76e-05	0.000149	CbGpPWpGaD
Suramin—F2—Signaling Pathways—S100B—urinary bladder cancer	3.75e-05	0.000149	CbGpPWpGaD
Suramin—PLA2G4A—Metabolism—TYMS—urinary bladder cancer	3.73e-05	0.000148	CbGpPWpGaD
Suramin—PLA2G4A—Metabolism—NCOR1—urinary bladder cancer	3.69e-05	0.000146	CbGpPWpGaD
Suramin—PLA2G4A—Metabolism—GSTM1—urinary bladder cancer	3.69e-05	0.000146	CbGpPWpGaD
Suramin—PLA2G2A—Metabolism—EP300—urinary bladder cancer	3.67e-05	0.000146	CbGpPWpGaD
Suramin—FSHR—Signaling Pathways—HRAS—urinary bladder cancer	3.66e-05	0.000145	CbGpPWpGaD
Suramin—F2—Signaling by GPCR—RHOA—urinary bladder cancer	3.56e-05	0.000141	CbGpPWpGaD
Suramin—PLA2G4A—Metabolism—GPX1—urinary bladder cancer	3.54e-05	0.00014	CbGpPWpGaD
Suramin—PLA2G4A—Metabolism—ERCC2—urinary bladder cancer	3.47e-05	0.000137	CbGpPWpGaD
Suramin—F2—GPCR downstream signaling—CXCL8—urinary bladder cancer	3.44e-05	0.000136	CbGpPWpGaD
Suramin—PLA2G4A—Hemostasis—KRAS—urinary bladder cancer	3.44e-05	0.000136	CbGpPWpGaD
Suramin—PLA2G4A—Signaling Pathways—S100B—urinary bladder cancer	3.43e-05	0.000136	CbGpPWpGaD
Suramin—F2—Signaling Pathways—NCOR1—urinary bladder cancer	3.37e-05	0.000134	CbGpPWpGaD
Suramin—F2—Hemostasis—TP53—urinary bladder cancer	3.34e-05	0.000132	CbGpPWpGaD
Suramin—F2—GPCR downstream signaling—IL2—urinary bladder cancer	3.29e-05	0.00013	CbGpPWpGaD
Suramin—PLA2G4A—Metabolism—MTHFR—urinary bladder cancer	3.26e-05	0.000129	CbGpPWpGaD
Suramin—PLA2G4A—Signaling by GPCR—RHOA—urinary bladder cancer	3.25e-05	0.000129	CbGpPWpGaD
Suramin—F2—Hemostasis—HRAS—urinary bladder cancer	3.19e-05	0.000127	CbGpPWpGaD
Suramin—F2—Signaling by GPCR—CXCL8—urinary bladder cancer	3.12e-05	0.000124	CbGpPWpGaD
Suramin—PLA2G4A—Signaling Pathways—NCOR1—urinary bladder cancer	3.09e-05	0.000122	CbGpPWpGaD
Suramin—PLA2G4A—Hemostasis—TP53—urinary bladder cancer	3.06e-05	0.000121	CbGpPWpGaD
Suramin—F2—Signaling by GPCR—IL2—urinary bladder cancer	2.99e-05	0.000118	CbGpPWpGaD
Suramin—F2—Signaling Pathways—TERT—urinary bladder cancer	2.97e-05	0.000118	CbGpPWpGaD
Suramin—PLA2G4A—Hemostasis—HRAS—urinary bladder cancer	2.92e-05	0.000116	CbGpPWpGaD
Suramin—PLA2G4A—Signaling by GPCR—CXCL8—urinary bladder cancer	2.86e-05	0.000113	CbGpPWpGaD
Suramin—PLA2G4A—Signaling by GPCR—IL2—urinary bladder cancer	2.73e-05	0.000108	CbGpPWpGaD
Suramin—F2—Signaling Pathways—FGFR3—urinary bladder cancer	2.73e-05	0.000108	CbGpPWpGaD
Suramin—PLA2G4A—Signaling Pathways—TERT—urinary bladder cancer	2.72e-05	0.000108	CbGpPWpGaD
Suramin—F2—Signaling Pathways—ESR1—urinary bladder cancer	2.65e-05	0.000105	CbGpPWpGaD
Suramin—PLA2G4A—Metabolism—PPARG—urinary bladder cancer	2.65e-05	0.000105	CbGpPWpGaD
Suramin—PLA2G4A—Metabolism—CREBBP—urinary bladder cancer	2.54e-05	0.000101	CbGpPWpGaD
Suramin—PLA2G4A—Signaling Pathways—FGFR3—urinary bladder cancer	2.5e-05	9.89e-05	CbGpPWpGaD
Suramin—PLA2G4A—Signaling Pathways—ESR1—urinary bladder cancer	2.42e-05	9.6e-05	CbGpPWpGaD
Suramin—F2—Signaling Pathways—CREBBP—urinary bladder cancer	2.32e-05	9.2e-05	CbGpPWpGaD
Suramin—F2—Signaling Pathways—IGF1—urinary bladder cancer	2.29e-05	9.09e-05	CbGpPWpGaD
Suramin—F2—Signaling by GPCR—EGFR—urinary bladder cancer	2.28e-05	9.04e-05	CbGpPWpGaD
Suramin—F2—Signaling by GPCR—KRAS—urinary bladder cancer	2.16e-05	8.54e-05	CbGpPWpGaD
Suramin—PLA2G4A—Signaling Pathways—CREBBP—urinary bladder cancer	2.13e-05	8.42e-05	CbGpPWpGaD
Suramin—F2—Signaling Pathways—RHOA—urinary bladder cancer	2.1e-05	8.33e-05	CbGpPWpGaD
Suramin—PLA2G4A—Signaling Pathways—IGF1—urinary bladder cancer	2.1e-05	8.31e-05	CbGpPWpGaD
Suramin—PLA2G4A—Signaling by GPCR—EGFR—urinary bladder cancer	2.09e-05	8.27e-05	CbGpPWpGaD
Suramin—PLA2G4A—Metabolism—PTGS2—urinary bladder cancer	2.08e-05	8.24e-05	CbGpPWpGaD
Suramin—PLA2G4A—Signaling by GPCR—KRAS—urinary bladder cancer	1.97e-05	7.81e-05	CbGpPWpGaD
Suramin—F2—Signaling Pathways—ERBB2—urinary bladder cancer	1.95e-05	7.71e-05	CbGpPWpGaD
Suramin—PLA2G4A—Signaling Pathways—RHOA—urinary bladder cancer	1.92e-05	7.62e-05	CbGpPWpGaD
Suramin—F2—Signaling Pathways—CXCL8—urinary bladder cancer	1.85e-05	7.31e-05	CbGpPWpGaD
Suramin—F2—Signaling by GPCR—HRAS—urinary bladder cancer	1.83e-05	7.26e-05	CbGpPWpGaD
Suramin—PLA2G4A—Metabolism—PTEN—urinary bladder cancer	1.81e-05	7.19e-05	CbGpPWpGaD
Suramin—PLA2G4A—Signaling Pathways—ERBB2—urinary bladder cancer	1.78e-05	7.05e-05	CbGpPWpGaD
Suramin—F2—Signaling Pathways—IL2—urinary bladder cancer	1.76e-05	6.99e-05	CbGpPWpGaD
Suramin—PLA2G4A—Metabolism—EP300—urinary bladder cancer	1.73e-05	6.86e-05	CbGpPWpGaD
Suramin—F2—Signaling Pathways—CCND1—urinary bladder cancer	1.72e-05	6.81e-05	CbGpPWpGaD
Suramin—PLA2G4A—Signaling Pathways—CXCL8—urinary bladder cancer	1.69e-05	6.69e-05	CbGpPWpGaD
Suramin—PLA2G4A—Signaling by GPCR—HRAS—urinary bladder cancer	1.68e-05	6.64e-05	CbGpPWpGaD
Suramin—F2—Signaling Pathways—MMP9—urinary bladder cancer	1.67e-05	6.61e-05	CbGpPWpGaD
Suramin—F2—Signaling Pathways—CDKN1A—urinary bladder cancer	1.66e-05	6.59e-05	CbGpPWpGaD
Suramin—F2—Signaling Pathways—PTEN—urinary bladder cancer	1.66e-05	6.57e-05	CbGpPWpGaD
Suramin—PLA2G4A—Signaling Pathways—IL2—urinary bladder cancer	1.61e-05	6.39e-05	CbGpPWpGaD
Suramin—F2—Signaling Pathways—EP300—urinary bladder cancer	1.58e-05	6.27e-05	CbGpPWpGaD
Suramin—PLA2G4A—Signaling Pathways—CCND1—urinary bladder cancer	1.57e-05	6.23e-05	CbGpPWpGaD
Suramin—F2—Signaling Pathways—SRC—urinary bladder cancer	1.54e-05	6.1e-05	CbGpPWpGaD
Suramin—PLA2G4A—Signaling Pathways—MMP9—urinary bladder cancer	1.53e-05	6.05e-05	CbGpPWpGaD
Suramin—PLA2G4A—Signaling Pathways—CDKN1A—urinary bladder cancer	1.52e-05	6.03e-05	CbGpPWpGaD
Suramin—PLA2G4A—Signaling Pathways—PTEN—urinary bladder cancer	1.52e-05	6.01e-05	CbGpPWpGaD
Suramin—PLA2G4A—Signaling Pathways—EP300—urinary bladder cancer	1.45e-05	5.73e-05	CbGpPWpGaD
Suramin—PLA2G4A—Signaling Pathways—SRC—urinary bladder cancer	1.41e-05	5.57e-05	CbGpPWpGaD
Suramin—F2—Signaling Pathways—MYC—urinary bladder cancer	1.38e-05	5.46e-05	CbGpPWpGaD
Suramin—F2—Signaling Pathways—EGFR—urinary bladder cancer	1.35e-05	5.34e-05	CbGpPWpGaD
Suramin—F2—Signaling Pathways—KRAS—urinary bladder cancer	1.27e-05	5.05e-05	CbGpPWpGaD
Suramin—PLA2G4A—Signaling Pathways—MYC—urinary bladder cancer	1.26e-05	5e-05	CbGpPWpGaD
Suramin—PLA2G4A—Signaling Pathways—EGFR—urinary bladder cancer	1.23e-05	4.89e-05	CbGpPWpGaD
Suramin—PLA2G4A—Signaling Pathways—KRAS—urinary bladder cancer	1.17e-05	4.62e-05	CbGpPWpGaD
Suramin—F2—Signaling Pathways—TP53—urinary bladder cancer	1.13e-05	4.49e-05	CbGpPWpGaD
Suramin—F2—Signaling Pathways—HRAS—urinary bladder cancer	1.08e-05	4.29e-05	CbGpPWpGaD
Suramin—PLA2G4A—Signaling Pathways—TP53—urinary bladder cancer	1.04e-05	4.1e-05	CbGpPWpGaD
Suramin—PLA2G4A—Signaling Pathways—HRAS—urinary bladder cancer	9.91e-06	3.92e-05	CbGpPWpGaD
